VKA or LMWH in Pediatric Subjects with Congenital or Acquired Heart Disease on Chronic Anticoagulation for Thromboembolism Prevention Description: This is a multi-center, randomized trial designed to assess the safety and pharmacokinetics of the anticoagulation agent Apixaban compared to conventional anticoagulation drugs in children with acquired and congenital heart disease. Mah DY, Cheng H, Alexander ME, Sleeper L, Newburger JW, del Nido PJ, Thiagarajan RR, Rajagopal SK. Correlates of Achieving Statin Therapy Goals in Children and Adolescents with Dyslipidemia.
At Boston Children’s Hospital, up to 40 children between 2 to Title: Pharmacodynamics, Pharmacokinetics, Safety and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 to 8 Years of Age after the Fontan Description: This prospective, open label active controlled multi-center study is tasked with the goal to evaluate the safety and optimal dosing of rivaroxaban (an oral anticoagulation agent) compared to acetylsalicylic acid for thrombus prevention in children aged 2 to 8 years with single ventricle physiology who have completed the Fontan procedure. Lin Z, Guo H, Cao Y, Zohrabian S, Zhou P, Ma Q, Van Dusen N, Guo Y, Zhang J, Stevens SM, Liang F, Quan Q, van Gorp PR, Li A, Dos Remedios C, He A, Bezzerides VJ, Pu WT. Acetylation of VGLL4 Regulates Hippo-YAP Signaling and Postnatal Cardiac Growth. Heart block following stage 1 palliation of hypoplastic left heart syndrome.
Enrollment goal: 200 Primary investigator: Meena Nathan, MD Contact: Bre Piekarski, RN, BSN: Breanna.
[email protected] 617-919-4457 Title: Preserved Umbilical Vein Use as Autologous Shunt Conduits in Neonatal Cardiac Surgery Description: This is a safety and feasibility trial to evaluate the use of autologous umbilical vein as shunts/ conduits, as well as patches in neonatal cardiac surgery.
[email protected] 617-919-4457 Title: Assessing the Use of a Preventive Cardiology Lifestyle Screening (PCLS) Tool in a Pediatric Subspecialty Lipid Clinic Description: In order to facilitate care, the Preventive Cardiology providers have developed a Pediatric Preventive Cardiology Lifestyle (PCLS) questionnaire that we believe will enable our clinical practice to identify lipid-specific high-risk lifestyle behaviors in a way that: 1) identifies lifestyle behaviors as well as longer and more intensive research questionnaires; 2) either does not delay, or even speeds up data collection on relevant lifestyle behaviors; 3) results in high patient and provider satisfaction; and 4) results in no worsening in lipid outcomes compared to usual care. [email protected] 617-355-4329 Title: Oral Treprostinil as Transition or Add-On Therapy for Pediatric Patients with PAH Description: This multi-center, open-label, multiple dose study investigates the safety, tolerability and pharmacokinetics of oral treprostinil in pediatric patients (ages 7-17) with PAH.
Enrollment goal: 28 Primary investigator: Lisa Bergersen, MD MPH Contact: Lisa Bergersen, MD, MPH: Lisa.
We will then deploy our newly developed questionnaire while continuing to monitor these factors for an additional 3-6 months. Cohort 3 patients are de novo prostacyclin subjects.
In this fashion, we plan to test time spent in lifestyle counseling, satisfaction, test-retest reliability, correlation with previously validated tools, and relationship to clinical outcomes. Enrollment goal: 5 Primary investigator: Mary Mullen MD, Ph D Contact: Alessandra Russo: Alessandra.
Eligible subjects will undergo one of the following one surgeries: VSD repair, To F repair or ASO. Ford MA, Gauvreau K, Mc Mullan DM, Almodovar MC, Cooper DS, Rycus PT, Thiagarajan R. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population.
Participants will receive open-label dexmedetomidine while in the operating room and up to 12 hours after surgery in the CICU. Factors Associated With Mortality in Neonates Requiring Extracorporeal Membrane Oxygenation for Cardiac Indications: Analysis of the Extracorporeal Life Support Organization Registry Data.